The EU Pharma Package is poised to reshape the commercial landscape for life science companies operating in Europe, with far-reaching implications for pricing, reimbursement negotiations and market access strategy across Member States. Reforms to exclusivity incentives and measures designed to accelerate generic entry could significantly influence pricing dynamics and the way companies approach reimbursement discussions across the region.
This session will explore how the EU Pharma Package could reshape pricing and reimbursement (P&R) dynamics across the EU, and what these changes may mean for your company’s strategic decisions around launch planning, portfolio prioritisation and long-term participation in the European life science market.
- How could changes to exclusivity incentives and earlier generic entry under the EU Pharma Package affect pricing dynamics across Member States?
- What implications might the reforms have for national P&R negotiations, including tender systems and reference pricing mechanisms?
- How might companies need to adapt their market access strategy and launch planning in response to increased pricing pressure?
- Could the reforms alter how companies prioritise product portfolios and decide whether and when to launch medicines in the European market?
Alexander Natz
